Cargando…
Obliterative bronchiolitis associated with rheumatoid arthritis: analysis of a single-center case series
BACKGROUND: Rheumatoid arthritis (RA) is a systemic autoimmune condition characterized by erosive inflammation of the joints. One rare pulmonary manifestation is obliterative bronchiolitis (OB), a small airways disease characterized by the destruction of bronchiolar epithelium and airflow obstructio...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013859/ https://www.ncbi.nlm.nih.gov/pubmed/29929518 http://dx.doi.org/10.1186/s12890-018-0673-x |
_version_ | 1783334107289223168 |
---|---|
author | Lin, Erica Limper, Andrew H. Moua, Teng |
author_facet | Lin, Erica Limper, Andrew H. Moua, Teng |
author_sort | Lin, Erica |
collection | PubMed |
description | BACKGROUND: Rheumatoid arthritis (RA) is a systemic autoimmune condition characterized by erosive inflammation of the joints. One rare pulmonary manifestation is obliterative bronchiolitis (OB), a small airways disease characterized by the destruction of bronchiolar epithelium and airflow obstruction. METHODS: We retrospectively reviewed the clinical data of patients with rheumatoid arthritis-associated obliterative bronchiolitis (RA-OB) from 01/01/2000 to 12/31/2015. Presenting clinical features, longitudinal pulmonary function testing, radiologic findings, and independent predictors of all-cause mortality were assessed. RESULTS: Forty one patients fulfilled criteria for diagnosis of RA-OB. There was notable female predominance (92.7%) with a mean age of 57 ± 15 years. Dyspnea was the most common presenting clinical symptom. Median FEV1 was 40% (IQR 31–52.5) at presentation, with a mean decline of − 1.5% over a follow-up period of thirty-three months. Associated radiologic findings included mosaic attenuation and pulmonary nodules. A majority of patients (78%) received directed therapy including long-acting inhalers, systemic corticosteroids or other immunosuppressive agents, and macrolide antibiotics. All-cause mortality was 27% over a median follow-up of sixty-two months (IQR 32–113). No distinguishable predictors of survival at presentation were found. CONCLUSIONS: RA-OB appears to have a stable clinical course in the majority of patients despite persistent symptoms and severe obstruction based on presenting FEV1. |
format | Online Article Text |
id | pubmed-6013859 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60138592018-07-05 Obliterative bronchiolitis associated with rheumatoid arthritis: analysis of a single-center case series Lin, Erica Limper, Andrew H. Moua, Teng BMC Pulm Med Research Article BACKGROUND: Rheumatoid arthritis (RA) is a systemic autoimmune condition characterized by erosive inflammation of the joints. One rare pulmonary manifestation is obliterative bronchiolitis (OB), a small airways disease characterized by the destruction of bronchiolar epithelium and airflow obstruction. METHODS: We retrospectively reviewed the clinical data of patients with rheumatoid arthritis-associated obliterative bronchiolitis (RA-OB) from 01/01/2000 to 12/31/2015. Presenting clinical features, longitudinal pulmonary function testing, radiologic findings, and independent predictors of all-cause mortality were assessed. RESULTS: Forty one patients fulfilled criteria for diagnosis of RA-OB. There was notable female predominance (92.7%) with a mean age of 57 ± 15 years. Dyspnea was the most common presenting clinical symptom. Median FEV1 was 40% (IQR 31–52.5) at presentation, with a mean decline of − 1.5% over a follow-up period of thirty-three months. Associated radiologic findings included mosaic attenuation and pulmonary nodules. A majority of patients (78%) received directed therapy including long-acting inhalers, systemic corticosteroids or other immunosuppressive agents, and macrolide antibiotics. All-cause mortality was 27% over a median follow-up of sixty-two months (IQR 32–113). No distinguishable predictors of survival at presentation were found. CONCLUSIONS: RA-OB appears to have a stable clinical course in the majority of patients despite persistent symptoms and severe obstruction based on presenting FEV1. BioMed Central 2018-06-22 /pmc/articles/PMC6013859/ /pubmed/29929518 http://dx.doi.org/10.1186/s12890-018-0673-x Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Lin, Erica Limper, Andrew H. Moua, Teng Obliterative bronchiolitis associated with rheumatoid arthritis: analysis of a single-center case series |
title | Obliterative bronchiolitis associated with rheumatoid arthritis: analysis of a single-center case series |
title_full | Obliterative bronchiolitis associated with rheumatoid arthritis: analysis of a single-center case series |
title_fullStr | Obliterative bronchiolitis associated with rheumatoid arthritis: analysis of a single-center case series |
title_full_unstemmed | Obliterative bronchiolitis associated with rheumatoid arthritis: analysis of a single-center case series |
title_short | Obliterative bronchiolitis associated with rheumatoid arthritis: analysis of a single-center case series |
title_sort | obliterative bronchiolitis associated with rheumatoid arthritis: analysis of a single-center case series |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013859/ https://www.ncbi.nlm.nih.gov/pubmed/29929518 http://dx.doi.org/10.1186/s12890-018-0673-x |
work_keys_str_mv | AT linerica obliterativebronchiolitisassociatedwithrheumatoidarthritisanalysisofasinglecentercaseseries AT limperandrewh obliterativebronchiolitisassociatedwithrheumatoidarthritisanalysisofasinglecentercaseseries AT mouateng obliterativebronchiolitisassociatedwithrheumatoidarthritisanalysisofasinglecentercaseseries |